Cargando cotizaciones...
Previsión
| Comprar |
7 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
Matinas BioPharma: CEO Jerome Jabbour named interim CFO
The board of directors of Matinas BioPharma appointed Jerome D. Jabbour, effective immediately, as interim chief financial officer in addition to his roles as chairman, president and CEO. The appointment follows the resignation of Keith Kucinski, who stepped down effective January 17, 2026, and will remain in place until a successor is named or another decision is made. The company stated that Jabbour’s compensation and employment terms remain unchanged, that there are no special arrangements or familial relationships, and that it has adjusted its change‑of‑control retention bonus rules through June 30, 2026. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -3,5 mil | 96,67 % |
| Beneficio neto | -1,16 M | 73,89 % |
| EBITDA | -1,56 M | 64,79 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1,11 M € |
Número de acciones | 6,41 M |
Máximo/mínimo de 52 semanas | 1,85 € - 0,15 € |
| Dividendos | No |
Beta | 1,75 |
Ratio P/E | -0,17 |
Ratio PEG | 0,00 |
Ratio P/B | 0,71 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | Matinas BioPharma Aktie |
| CEO | Jerome D. Jabbour |
| Empleados | 2 |
Descubrir activos
Los accionistas de Matinas BioPharma Aktie también invierten en los siguientes activos
